Purpose. This paper describes the clinical history and radiographic appearance of second m alignancies in patients with bilateral retinoblastom a. Subjects/m ethods. The imaging studies and clinical data of 14 patients with a history of bilateral retinoblastoma who were treated for second malignancies were reviewed. Results. A total of 17 tumors were identi® ed in 14 patients during the period 1978± 1996. The median age of occurrence of the second malignancy was 17 years (range 10± 32 years). Fourteen of the 17 malignancies occurred in the facial structures and three developed in the lower extremities. The histologies included osteosarcoma (n 5 5), m alignant ® brous histiocytoma (n 5 3), high-grade spindle cell sarcoma (n 5 3), malignant mesenchymoma (n 5 l), leiomyosarcoma (n 5 4) and angiosarcoma (n 5 l). The tumors were locally aggressive and had a similar appearance to those found in nonretinoblastoma patients. Six of the 14 patients are alive and disease free. D iscussion. M ost of the adolescent and young adult retinoblastoma survivors developed second m alignancies in the irradiated facial structures but some occurred in distal sites. Radiologically, these tumors do not differ in appearance from those seen in non-retinoblastoma patients with the exception of their location.
Introduction
Retinoblastom a (RB) is a rare ocular neoplasm of childhood which occurs in a sporad ic or hereditary form . W hile the sporadic form typically presents w ith unilateral disease, m ost patients with the hereditary form have bilateral retinoblastom a (BRB). T he hereditary form is asso ciated with a germ -line defect in the retinoblastom a gene, RB -1, on chrom osom e 13 and is transm itted in an autosomal dom inant pattern. Prognosis for patients with BRB is excellent w ith approxim ately 90% of patients achieving cure of the prim ary disease.
1,2 However, these sam e patients are at an increased risk of developing a second m alignancy (SM ). 3± 5 This pap er sum marizes the experience at our institution regarding second m alignancies in patients treated for BRB and describes the radiographic features.
S ubjects and m ethods
A series of 14 patients w ith BRB presenting with a SM was obtained via a search of the M emorial H ospital database. Retrospective analysis of the charts, pathology and radiologic studies were perform ed.
Results
A total of 14 patients with BRB w ere treated for a second m alignancy at our institution during the period 1978± 1996. T ables 1 and 2 sum m arize the clinical history and outcom e of these 14 patients. Thirteen of the patients were diagnosed w ith BRB by 21 m onths of age. O ne patient (12) is included in the series because his unilateral RB was m ulti-focal and he has a fam ily history of RB. Each patient initially underw ent enucleation of one globe and m ost patients had radiation therapy given to the opposite eye. T wo of the patients had radiation therapy to both eyes. Initial radiation therapy doses ranged from 3575 cGy to 5400 cGy. T he radiation doses for six of the patients could not be ascertained as their radiation treatm ent was perform ed elsewhere. T he age at diagnosis of the SM ranged from 10 to 32 years with a m edian age of 17 years. Patient 6 was diagnosed with a SM at 16 years of age, and then developed a third m alignancy at age 18 years . This third malignancy, m alignant ® brous histiocytoma (MF H) in the right orbit, was different in location and histology than the second m alignancy, an osteosarcom a of the left tibia.
Patient 10 developed a third m alignancy, angiosarcom a of the upper lip, 16 m onths after radiation therapy for leiomyosarcom a of the right ethmoid sinus.
Patient 11 developed an osteosarcom a of the fem ur 13 years after treatment for BRB and a leiom yosarcom a within the facial radiation ® eld 22 years after irradiation.
The histologies of the m alignancies included ® ve osteosarcom as (OS), three high-grade spindle cell sarcom as (H GS), one angiosarcom a, one m alignant m esenchym om a, three m alignant ® brous histiocytom as (M FN ) and four leiomyosarcom as (LM S). F ourteen of the 17 SM occurred within the facial structures; six know n to be w ithin the radiation port. In six patients, it is highly likely that the SM occurred in the radiation port. One patient w hose SM was not in the facial bones ultimately developed a third m alignancy w ithin the radiated facial structures.
Radiograph ically, the O S in these patients had a sim ilar appearance to those in non-B RB patients. T he tum ors dem onstrated a combination of osteolysis and osteosclerosis and an asso ciated soft tissue m ass. Osteoid matrix w as also present (Fig. 1) . Enhancem ent of these lesions was present on the contrast-enhanced com puted tom ography (C T) and m agnetic resonance im aging (M RI) studies. T he location of the O S, how ever, was unusual. O ne of the ® ve O S developed in the long bones (the comm on location for de novo OS) while the other four developed in the facial bones.
The MF H were heterogeneous-enhancing lesions which caused osseous destruction which was typically perm eative. Like the OS, the MF H had an appearance sim ilar to that of a de novo M FH but the location was unusual.
The three cases of H GS app eared as inhom ogeneous m asses with central necrosis and contrast enhancement on M RI and CT . T he tum ors caused destruction of the adjacent osseous structures but no m atrix was seen in the soft tissue com ponent. In one case, patient 4, the H GS started in the left orbit and caused proptosis of the left globe.
Four patients developed a LM S in our group. This heterogeneous soft tissue tum or in® ltrated the paran asal sinuses, and sometimes extended to the orbit and extended intracranially to destroy the skull base.
Intracranial extension of the tum or was not uncom m on. T hree had intracranial tumor at the time of presentation; patient 5 with M FH , patient 4 with H GS (Fig. 2) (Fig. 3) and later intrapulmonary disease.
N ine of the 14 patients in this study experienced recurrence of their tum ors.
Other radiographic features com m on to these patients are asso ciated with the therapy they received (a)
as treatment for their BRB or SM . H ypotelorism resulting from radiation-induced bone injury to the orbit and adjacent bony structures was seen in several patients. C erebral white m atter changes from radiation and chemotherapy were visible on M RI. Six of the 14 patients have died of causes related to their malignancies, after surviving a m edian of 31 m onths from diagnosis of the SM . E ight patients are alive, of which six are disease free at a m edian of 58 m onths after the SM w as diagnosed. Two others are alive w ith residual disease.
D iscussion
It has been recognized that patients with BRB are at greater risk of developing a SM . Abram son et al. determ ined that tw o-thirds of the second tum ors arise within the ® eld of radiation therapy and onethird are outside the ® eld. 2 T his suggests that radiation therapy used to treat retinoblastom a m ay play a part in the induction of the SM but there m ust also be a genetic predisposition. G enetic studies have demonstrated that the RB-1 gene w hose deletion is responsible for retinoblastom a is localized on band 14 of the long arm of chrom osom e 13. RB-1 m utations have also been identi® ed in OS. 6± 8 In our study, all the patients received radiation therapy as part of their treatm ent for BRB and developed a sarcom a within the ® eld of radiation. As with radiation-induced sarcom as in non-R B patients, the sarcom as developed after a long latency period. Our patients were diagnosed and treated for BRB in infancy. The sarcom as w hich they developed occurred one to three decades later at a m edian age of 17 years with a range of 10± 32 years. Radiation-induced sarcom as in non-R B patients have been reported to develop 4± 30 years after com pletion of radiation therapy. 10 The doses of radiation used to treat our patients were in the range which can result in osseous damage. D oses greater than 3000 cGy usually cause permanent dam age to reparative m echanisms while doses greater than 5000 cG y can cause devitalization of bones. 10 T hese num bers were determined for adult bones; children m ay m ore favorably tolerate higher doses. Kin et al. review ed the radiationinduced sarcomas of bone following therapeutic radiation at the Mem orial Sloan Kettering Cancer C enter from 1977 to 1982. 11 The age of the 10 patients in his study ranged from 9 to 52 years with ® ve patients under 18 years of age. He found both osseous and extraosseous sarcom as can develop after receiving doses ranging from 3000 to 6000 cGy, w ith a m edian dose of 4605 cGy.
W ith the exception of their location, the radiographic appearance of the sarcom as in our patients w as sim ilar to those in non-B RB patients. In our study, only two of the ® ve O S developed in a long bone. T ypically, O S arise in the m etaphyseal region of the tubular bones with 50± 75% developing around the knee. O nly 5± 10% of de novo O S develop in the¯at bones 12 yet three of the ® ve O S in our patients developed there. The tumors were locally advanced at the time of their presentation and had a propensity to recur, w hich may account for the poor clinical outcom e for som e of these patients. At our institution, aggressive treatment for the SM is advocated. N eo-adjuvant chem otherapy produced responses in the m ajority of the patients treated and, with subsequent surgery, long periods of disease-free survival were obtained. Six of our 14 patients are alive w ithout evidence of disease, indicating that apparent cures can be achieved in a signi® cant m inority.
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